Verilumia 
Survodutide cuts weight, but side effects prompt dropouts
Boehringer Ingelheim’s investigational drug survodutide reduced body weight by as much as 13.1% over 76 weeks in adults with overweight or obesity and type 2 diabetes, according to results from the Phase 3 SYNCHRONIZE...
